Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galapagos NV ADR (NQ: GLPG )

38.64 +1.11 (+2.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 250,987
Open 37.74
Bid (Size) 38.64 (2)
Ask (Size) 38.67 (5)
Prev. Close 37.53
Today's Range 37.74 - 38.74
52wk Range 36.16 - 72.11
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Earnings Preview For Galapagos
 
Via Benzinga

Performance

YTD
-12.87%
-12.87%
1 Month
+2.68%
+2.68%
3 Month
-12.93%
-12.93%
6 Month
-9.38%
-9.38%
1 Year
-37.70%
-37.70%

More News

Read More
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
Via Benzinga
Why Galapagos Stock Is Falling Today
Via Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
Via Benzinga
Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
Via Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
Expert Ratings for Galapagos
Via Benzinga
3 Biotech Stocks to Sell in October
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Via Benzinga
Lyft, DoorDash, Expedia And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Mid-Afternoon Market Update: US Stocks Turns Lower In Volatile Trading; Nasdaq Tumbles 150 Points
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.